What 300 million lab tests show about midlife, on average, and what to ask at your next check-up

What 300 million lab tests show about midlife, on average, and what to ask at your next check-up

If you've ever wondered what menopause blood tests can actually tell you, a large new study offers a useful, and easily misread, answer. Researchers analyzed more than 300 million laboratory tests from more than 1 million women and found that, on average, many routine markers shift in a step-like way around the final menstrual period (Nature Medicine). This post explains what the findings mean for your midlife check-ups, and what they don't. For a fuller look at the study and why some experts question the "cliff" label, see our earlier post, Is menopause a physiological cliff?

The study in brief

The study, led by Uri Alon's team at the Weizmann Institute of Science and published in Nature Medicine on October 12, 2026, used a computer method to line up US and Israeli lab records by estimated time from the final period, since records rarely note when that was (Nature Medicine). On average, 52 of 90 lab measures shifted abruptly around the final period in women but not in men, most notably markers of bone, liver, lipids (blood fats) and fluid balance, with kidney markers also shifting; iron and red-blood-cell measures improved, likely because periods stop (same source). Hormone changes began much earlier: on average, AMH began falling faster about 15 years before the final period, FSH began rising faster about 14 years before, and estradiol began falling faster about 12 years before (same source).

Menopause blood tests: what this means, and what it doesn't

What it means. Menopause is a whole-body transition, not only the end of periods. Knowridge's summary puts it well: the "cliff" describes "a step in the average pattern of test results, not a sudden collapse in every woman's health" (Knowridge). The authors suggest midlife is a window when preventive care may matter, and say their timeline extends that window to almost a decade before menopause (Nature Medicine).

What it doesn't mean:

• It's not a prediction about you. The authors state plainly that their method "does not predict the FMP time for each individual" (Nature Medicine). These are population averages. Knowridge adds that it is "not a proven personal countdown to menopause" (Knowridge).
• It's not proof of cause and effect. The study relied on retrospective, cross-sectional data and self-reported menopause status. The authors say this can't replace a study that follows the same women through the transition (Nature Medicine).
• The "cliff" label is debated. Some outside experts question it. Martha Hickey, head of menopause services at The Women's Hospital Victoria, who wasn't involved in the study, called the claim of "cliff-like" changes "unnecessarily alarming" for women and said "Physiological cliff is not a scientific or medical term" (ABC News Australia).
• A lab shift isn't a diagnosis. Not every test change carries the same meaning or importance, and more research is needed to connect these patterns with symptoms and health outcomes (Knowridge).

What about hormone therapy?

Women who reported using menopausal hormone therapy had smaller shifts in many measures, especially bone, liver and kidney tests (Nature Medicine). That's an association, not proof of benefit. Hormone therapy users made up only 9% of the US participants and may differ from non-users in health, symptoms and access to care. The authors say adjusting for this "cannot entirely eliminate healthy user bias" and that the effects of hormone therapy "need to be tested by prospective randomized trials" (same source). Not every marker looked better, either: hormone therapy was associated with higher C-reactive protein (CRP), an inflammation marker, which the authors say fits earlier studies showing oral, but not transdermal (patch), estrogen can raise CRP (same source).

So this study is not a reason to start hormone therapy to "prevent the cliff." The American College of Obstetricians and Gynecologists (ACOG) recommends that starting hormone therapy be a shared decision with a clinician, based on your symptoms, age, medical history and baseline risks of cardiovascular disease, breast cancer and blood clots. If it's chosen, ACOG recommends starting before age 60 or within 10 years of menopause, in people without contraindications (ACOG). Our summary of ACOG's new menopause guidance covers the details.

Midlife labs and check-ups to ask a clinician about

ACOG's October 2026 guidance focuses on treating hot flashes, night sweats, sleep and mood symptoms. It also calls for earlier, more comprehensive education about menopause so women can recognize symptoms and seek care sooner (ACOG). It doesn't set out a menopause lab panel, and this study doesn't suggest ordering all 90 tests. What it does is give you a reason to make midlife a check-in point. Questions you could bring:

1. Based on my age and history, which routine checks are due: blood pressure, a lipid (cholesterol) panel, and blood sugar testing?
2. Should my kidney and liver function be checked as part of routine blood work?
3. What's my risk of bone loss, and when would a bone density scan make sense for me? (The study found osteoporosis rose faster after menopause in women than in men (Nature Medicine).)
4. If I'm noticing perimenopause symptoms, what will a hormone test tell us, and what won't it?
5. My sleep or mood has changed. Could it be connected to menopause, and what are my options? (ACOG's guidance covers hormonal, nonhormonal and non-drug options, including cognitive behavioral therapy and exercise (ACOG).)
6. If I'm considering hormone therapy, how do my personal risks weigh against the benefits?

Heart health is a big part of this conversation. Our post on menopause and heart risk goes deeper on what to check.

The bottom line

This is one of the largest looks yet at how the body changes around menopause, and it suggests the shift is sharper and broader than a gradual slope. But it describes averages across very large groups, not your personal future, and it can't show that hormone therapy prevents these changes. The practical takeaway is simple: midlife is a good time for a thorough check-up and an honest conversation about symptoms and risks.

Ready to talk it through? Start a visit with a licensed Kindr Health provider →

A licensed provider will determine whether treatment is appropriate; prescriptions are not guaranteed and depend on a clinician's evaluation.

Medical disclaimer: This article is for educational purposes only and is not a substitute for individual medical advice, diagnosis or treatment. Kindr Health is a telehealth platform connecting patients with licensed providers. Not an emergency service. If you are experiencing a medical emergency, call 911. Prescription medications require clinical evaluation. Individual results vary.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
NPI 1609792902 · Last reviewed: October 19, 2026